{
    "clinical_study": {
        "@rank": "46795", 
        "arm_group": [
            {
                "arm_group_label": "AL-4943A", 
                "arm_group_type": "Experimental", 
                "description": "AL-4943A ophthalmic solution, 1 drop per eye, 2 non-consecutive days"
            }, 
            {
                "arm_group_label": "AL-4943A Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "AL-4943A ophthalmic solution vehicle, 1 drop per eye, 2 non-consecutive days"
            }, 
            {
                "arm_group_label": "PATADAY", 
                "arm_group_type": "Active Comparator", 
                "description": "Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop per eye, 2 non-consecutive days"
            }, 
            {
                "arm_group_label": "PATANOL", 
                "arm_group_type": "Active Comparator", 
                "description": "Olopatadine hydrochloride ophthalmic solution, 0.1%, 1 drop per eye, 2 non-consecutive days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate an ophthalmic solution for the treatment of ocular\n      itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge\n      (CAC) model."
        }, 
        "brief_title": "Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Allergic Conjunctivitis", 
        "condition_browse": {
            "mesh_term": [
                "Conjunctivitis", 
                "Conjunctivitis, Allergic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Enrolled participants will be tested for the presence of common allergies using the\n      Conjunctival Allergen Challenge (CAC) model. Drops of increasing concentration of a\n      solubilized allergen will be instilled in both eyes until a positive reaction occurs. The\n      test will be repeated to confirm the allergic reaction.  Participants with confirmed\n      reactions will be administered the test article (Day 0) and undergo a CAC 24 hours\n      post-instillation (Day 1). On Day 14, participants will be administered the test article and\n      undergo an additional CAC."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Able to be dosed in both eyes, able and willing to make the required study visits and\n             to follow instructions.\n\n          -  Negative urine pregnancy test if female of childbearing potential and use  adequate\n             birth control throughout the study period.\n\n          -  Diagnostic skin test indicative of allergy for cat hair, cat dander, grasses,\n             ragweed, dust mite, dog dander, cockroach and/or trees within 24 months prior to\n             Visit 1 or at Visit 1.\n\n          -  History of seasonal or perennial allergic conjunctivitis for at least 1 year prior to\n             Visit 1.\n\n          -  Best-corrected visual acuity of 55 or greater in each eye as measured by ETDRS\n             (letters read method).\n\n          -  Manifest a positive bilateral Conjunctival Allergen Challenge (CAC) test response.\n\n          -  Willing to discontinue contact lens wear for at least 72 hours prior to Visit 1 and\n             throughout the study.\n\n          -  Other protocol-defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Known history or presence of persistent dry eye syndrome, or currently requires\n             frequent use of artificial tears, gels or lubricants, presence of punctal plugs, use\n             of Restasis\u00ae, or topical ocular corticosteroids for dryness of eyes.\n\n          -  Presence of an ocular condition that may affect the study outcomes.\n\n          -  History or evidence of ocular surgery (including refractive procedures such as LASIK,\n             PRK and RK) within 6 months of Visit 1.\n\n          -  Presence of signs/symptoms of active allergic conjunctivitis at the start of Visits\n             1, 2, 3A, or 4.\n\n          -  History of anaphylactic reaction to any allergens used in this study.\n\n          -  Current evidence or recent (within 6 months) history of severe, unstable, or\n             uncontrolled medical conditions and/or other relevant systemic diseases.\n\n          -  Use of any disallowed medication during the period indicated prior to Visit 1.\n\n          -  Other protocol-defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "902", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01743027", 
            "org_study_id": "C-12-053"
        }, 
        "intervention": [
            {
                "arm_group_label": "AL-4943A", 
                "intervention_name": "AL-4943A ophthalmic solution", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "AL-4943A Vehicle", 
                "intervention_name": "AL-4943A ophthalmic solution vehicle", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "PATADAY", 
                "intervention_name": "Olopatadine hydrochloride ophthalmic solution, 0.2%", 
                "intervention_type": "Drug", 
                "other_name": "PATADAY\u00ae"
            }, 
            {
                "arm_group_label": "PATANOL", 
                "intervention_name": "Olopatadine hydrochloride ophthalmic solution, 0.1%", 
                "intervention_type": "Drug", 
                "other_name": "PATANOL\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Olopatadine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Allergic conjunctivitis", 
            "Olopatadine HCl solution", 
            "Conjunctival Allergen Challenge", 
            "Itching eyes", 
            "Ocular allergies", 
            "PATADAY", 
            "PATANOL"
        ], 
        "lastchanged_date": "July 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact Alcon Call Center for Trial Locations"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "overall_official": {
            "affiliation": "Alcon Research", 
            "last_name": "Undraa Altangerel, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "A CAC will be performed on Day 1, 24 hours after drop instillation on Day 0.  Ocular itching will be assessed by the patient post-CAC.", 
                "measure": "Ocular itching associated with allergic conjunctivitis at the 24 hours duration of action.", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "A CAC will be performed after drop instillation (Day 14). Ocular itching will be assessed by the patient pre-dose and post-CAC. This outcome measure is pre-specified for AL-4943A and AL-4943A Vehicle.", 
                "measure": "Ocular itching associated with allergic conjunctivitis at the onset of action", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01743027"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "A CAC will be performed after drop instillation (Day 14). Conjunctival redness will be assessed by the investigator pre-dose and post-CAC. This outcome measure is pre-specified for AL-4943A, PATADAY and AL-4943A Vehicle.", 
                "measure": "Conjunctival redness associated with allergic conjunctivitis at the onset of action", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }, 
            {
                "description": "A CAC will be performed after drop instillation (Day 14). Total redness will be assessed by the investigator pre-dose and post-CAC. This outcome measure is pre-specified for AL-4943A, PATANOL, and PATADAY.", 
                "measure": "Total redness associated with allergic conjunctivitis at the onset of action", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }, 
            {
                "description": "A CAC will be performed on Day 1, 24 hours after drop instillation on Day 0. Conjunctival redness will be assessed by the investigator post-CAC.", 
                "measure": "Conjunctival redness associated with allergic conjunctivitis at the 24 hours duration of action", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "A CAC will be performed on Day 1, 24 hours after drop instillation on Day 0. Total redness will be assessed by the investigator post-CAC. This outcome measure is pre-specified for AL-4943A, PATANOL, and PATADAY.", 
                "measure": "Total redness associated with allergic conjunctivitis at the 24 hours duration of action", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "A CAC will be performed on Day 1, 24 hours after drop instillation on Day 0. Ocular itching will be assessed by the patient post-CAC. A responder is defined as a patient with zero-itch (a score of zero on ocular itching for both eyes) or with at least 2 units reduction in ocular itching relative to the baseline confirmatory CAC score. This outcome measure is pre-specified for AL-4943A, PATANOL, and PATADAY.", 
                "measure": "Proportion of ocular itching responders at the 24 hours duration of action", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "A CAC will be performed after drop instillation (Day 14). Ocular itching will be assessed by the patient pre-dose and post-CAC. A responder is defined as a patient with zero-itch (a score of zero on ocular itching for both eyes) or with at least 2 units reduction in ocular itching relative to the baseline confirmatory CAC score. This outcome measure is pre-specified for AL-4943A, PATANOL, and PATADAY.", 
                "measure": "Proportion of ocular itching responders associated with allergic conjunctivitis at the onset of action", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }, 
            {
                "description": "A CAC will be performed on Day 1, 24 hours after drop instillation on Day 0. Ocular itching will be assessed by the patient post-CAC. This outcome measure is pre-specified for PATADAY and AL-4943A Vehicle.", 
                "measure": "Ocular itching associated with allergic conjunctivitis at the 24 hours duration of action", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }
        ], 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}